GlassScriptPhysician profile
Wayne J Berry
NPI 1508244435
$3,063.77
in general payments reported to CMS, 2019-2025
23 companies · $1,481 in 2025
The $1,481 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $264 · 2024: $1,319 · 2025: $1,481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,063.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $616.56 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $447.81 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $351.40 | 2023-2025 | Vraylar |
| Sumitomo Pharma America, INC. | $285.88 | 2023-2025 | Gemtesa |
| Lilly USA, LLC | $181.38 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $152.06 | 2024-2025 | |
| Mylan Specialty L.P. | $151.66 | 2023-2024 | Yupelri |
| Axsome Therapeutics, INC. | $121.62 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $109.24 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.27 | 2023-2025 | Jardiance |
| Pfizer INC. | $84.13 | 2024-2025 | |
| Dexcom, INC. | $76.95 | 2024 | Dexcom G7 Gss (161) |
| Phathom Pharmaceuticals, INC. | $64.81 | 2023-2025 | Voquezna |
| Corcept Therapeutics | $54.87 | 2025 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $49.10 | 2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $42.31 | 2025 | Gvoke Hypopen |
| Amgen INC. | $40.70 | 2023-2025 | Otezla, Otezla, Repatha |
| Kowa Pharmaceuticals America, INC. | $30.95 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $30.93 | 2023 | Xarelto |
| Viatris Specialty LLC | $27.98 | 2025 | Yupelri |
| Alnylam Pharmaceuticals INC. | $20.14 | 2025 | Givlaari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.58 | 2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $15.44 | 2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Berry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.